Similarly, FN improves impaired glucose tolerance through activation of PPAR‐α which inhibits BACE‐1, thereby reducing soluble APPβ and Aβ42 release and enhancing Aβ1‐42 clearance. Here, BACE1 is linked to Impaired glucose tolerance.